Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Featured Videos

ORLANDO, FL USA (UroToday.com) - Dr. Aria A. Razmaria and colleagues reported that previous literature Gleason pattern 6 prostate cancer lacks the ability to metastasize. The authors’ goals were to identify patients with Gleason score 6 and stage T3 disease during the time of diagnosis in addition to reevaluating the prostate tissue pathologies.

auaThe authors were able to include only 36 cases that met inclusion criteria of Gleason 6, extension outside of the prostate, or seminal vesicle invasion. Pathological slides were then re-reviewed by a GU pathologist for grade, stage, and extent of spread.

They found that 77% of their patients upgraded to 3+4 or 4+3. They also found that 5% had minor components of pattern 4, 9% were down-staged to T2, and 14% were purely Gleason score 6 and T3a stage. Of the cases that were re-reviewed, the authors did not observe any Gleason score 6 and stage T3b disease.

The authors concluded that in Gleason score 6 prostate cancer, they did not see any invasion of cancer into the seminal vesicles. However, they concluded that focal extraprostatic extension in Gleason score 6 cancers may be possible. The oncological relevance of these findings in presence of GLS 6 prostate cancer needs further evaluation. Clinical management can potentially change if these results are confirmed in that one can utilize a different treatment strategy based on the grade and stage of the cancer.

Presented by Aria A. Razmaria, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Chicago, IL USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
Calendar
Upcoming educational events
November 23-25, 2018 / European Society for Medical Oncology Asia 2018 Congress
European Society for Medical Oncology Asia 2018 Congress
November 25-30, 2018 / RSNA 2018 Annual Meeting
RSNA 2018 Annual Meeting
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018